Company: CERO
Filing Date: 2025-07-25
Form Type: 424B3
Source: 0001213900-25-067733
Chunk: 1

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-25
Form: 424B3
Chunk 1
---
 an “emerging growth company” under applicable federal securities laws and will be subject to reduced public company reporting requirements.

Investing in our securities involves a high degree of risk. Before buying any securities, you should carefully read the discussion of the risks of investing in our securities in “Risk Factors” beginning on page 8 of the Prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities to be issued under the Prospectus or determined if the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

<div align='center'>The date of this Prospectus Supplement is July 25, 2025.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 18, 2025

CERO THERAPEUTICS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)</div>

| Delaware                     |     | 001-40877               |     | 81-4182129         |
| (State or Other Jurisdiction 
 of Incorporation )           |     | -Commission File Number |     | -IRS Employer      
 Identification No. |

| 201 Haskins Way, Suite 230               
 South San Francisco, California          |     |     94080 |
| (Address of principal executive offices) |     | -Zip Code |

<div align='center'>Registrant’s telephone number, including area code: 650 -407-2376

(Former name or former address, if changed since last report)</div>

Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)                  |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)                 |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under